All In Biotech

Drug Trial Radar · NCT06285916

A Study to Assess the Efficacy, Safety, and Tolerability of Oral NORA520 in Adults With Severe Postpartum Depression

A Randomized, Placebo-Controlled, Double-Blinded, Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Oral NORA520 in Female Adults With Severe Postpartum Depression

Last checked: Nov 19, 2026Latest source record: Jul 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

93

Actual

Start

Mar 28, 2024

Primary completion

Sep 11, 2025

Study completion Oct 6, 2025

Sponsor

Lead sponsor
TWi Biotechnology, Inc.Industry
Sponsor type
Industry
First posted
Feb 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this research study is to test the study drug, NORA520, as a possible treatment for severe postpartum depression (PPD). The trial aims to determine: * How well NORA520 is tolerated and what side effects it may cause * If NORA520 reduces depressive symptoms in subjects with severe PPD * The amount of NORA520 in the blood at various times after taking the study drug; this provides information that helps determine how often NORA520 should be taken * In a subset of subjects, the amount of NORA520 in breastmilk at various times after taking it to determine if and how much NORA520 can pass into breastmilk Participate in this study will be randomly assigned to one of 3 different groups. All subjects will take the study drug for 3 days.

Conditions

  • Depression, Postpartum
  • Postpartum Depression
  • Post-partum Depression
  • Postnatal Depression
  • Post-Natal Depression

Interventions

  • NORA520 Dose 1Drug

    Oral NORA520 tablets Dose 1 for 3 days

  • NORA520 Dose 2Drug

    Oral NORA520 tablets Dose 2 for 3 days

  • PlaceboDrug

    Oral Placebo tablets for 3 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence, severity, and causality of AEs, SAEs, and AESIsTime frame: Up to Day 30
  2. Change from baseline in HAM-D17 total score compared to placeboTime frame: Baseline to Day 4

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • Pillar Clinical Research

    Bentonville, Arkansas

  • Advanced Research Center

    Anaheim, California

  • Alliance Research Institute

    Canoga Park, California

  • Cenexel Clinical Research

    Sherman Oaks, California

  • Cenexel Clinical Research

    Torrance, California

  • MedOne Clinical Research

    Miami, Florida

  • Meridian International Research, Inc.

    Miami Gardens, Florida

  • Combined Research

    Orlando, Florida

  • Clinical Research Center of Florida

    Pompano Beach, Florida

  • GCP Research

    St. Petersburg, Florida

  • Cenexel Clinical Research

    Atlanta, Georgia

  • CenExel Clinical Research

    Decatur, Georgia

  • CenExel Clinical Research

    Savannah, Georgia

  • Insight Hospital and Medical Center Chicago

    Chicago, Illinois

  • Zucker Hillside Hospital

    Glen Oaks, New York

  • Monroe Biomedical Research

    Monroe, North Carolina

  • Maximos Ob/Gyn

    League City, Texas

  • Pillar Clinical Researc

    Richardson, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.